I love it when things work out!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has Anyone Else noticed how immovable the bid seems to have become. It looks that not matter what they thow at it, it just gathers it in and executes a buy at the offer.
Granted I could be proved wrong by a pull back, but I think we may have the beginning of a move back up. Guess we will have to wait and see.
Oops....the bid was just smacked......and went up. Hmmm....!!!
According to Yahoo....the float is 32 Million.
Huge Block Trades Going Through as I type....
10K 15K 47K 20K etc. etc. I think we're going seriously higher.
IHUB Allows you to Edit your post for 15 minutes after it's submitted. RK
According to the last 10Q (it's always on the first page of the 10Qs and 10Ks.
As of May 31, 2007, the issuer had 43,417,618 shares of Common Stock, $.01 par value, outstanding.
Corning Inc (NYSE: GLW) Website Is Pretty Interesting
http://www.corning.com/Lifesciences/us-canada/en/inside_life_sciences/
Innovating Life Sciences Research
Corning Life Sciences brings new and innovative laboratory tools to researchers. Our core technical competencies include polymer science, biochemistry and molecular biology, glass melting and forming, surface modification, and characterization science. As part of Corning Incorporated, we are a world leader in specialty glass and have a 150-year tradition of innovation.
We are committed to meeting customers’ unique and changing needs with original solutions for today’s emerging life sciences technologies. Our dedication to quality, technology and innovation has enabled us to produce the world’s most comprehensive line of laboratory tools for life science research. Corning Life Sciences also offers custom capabilities such as special packaging, bar coding, and printed lot numbers, to meet specific customer requirements. Our key areas of expertise include:
Assay and HTS
Our commitment to innovation and surface technology has helped make us the world leader in microplates. We were first to introduce automation-friendly microplates for high-throughput screening, while our microplate standardization program ensures industry-wide compatibility.
Cell Culture
Our cell culture line includes dishes, flasks, microplates, Transwell® permeable supports, and cryogenic vials, which are versatile, consistent, and easy to use. For mass cell culture, we offer roller bottles, spinner flasks and CellCube® - the system that delivers more speed, efficiency, and productivity.
Liquid Handling
Our liquid handling instruments and disposable products deliver consistent, reliable performance for small- and medium-scale laboratory applications. Our products include Pyrex® beakers, autoclavable single-channel and multi-channel pipettors, serological pipettes, centrifuge tubes, graduated cylinders, and Erlenmeyer flasks.
Laboratory Filtration
With capacities ranging from microliters to several liters, our filtration products include syringe filters and vacuum filter systems, as well as storage bottles.
Building next generation manufacturing capabilities -- today
Corning Life Sciences’ products are manufactured using fully-automated processes for impeccably clean results. Corning’s high quality, high performance products are manufactured at six facilities: Kennebunk, Maine; Oneonta, New York; Big Flats, New York; Sunderland, England; Monterrey, Mexico; and Reynosa, Mexico. These state-of-the-art facilities follow stringent production guidelines providing you with the highest level of consistency and quality. We certify each order with quality control testing data, certificates of compliance, and detailed product descriptions. Our rigorous standards and certification programs exceed established industry guidelines.
Corning Life Sciences plastics manufacturing facilities are ISO 9002 registered. The Kennebunk, Maine, facility is ISO 9001 registered to the 2000 standards.
Corning Inc. (NYSE: GLW) Is a Large Company with Big Bucks
"Corning Incorporated provides technology-based products in the United States. It operates in four segments: Display Technologies, Telecommunications, Environmental Technologies, and Life Sciences....
"The Life Sciences segment offers laboratory products, including microplate products, coated slides, filter plates, plastic cell culture dishes, flasks, cryogenic vials, roller bottles, mass cell culture products, liquid handling instruments, glass beakers, pipettors, serological pipettes, centrifuge tubes, and laboratory filtration products."
They must have seen something in MCET products that they like...that has the potential to make some $$$$.
Plus GLW has $3.2 Billion in Cash on hand!!!
I was checking the time and sales there was a 100K share purchase at 20 cents. Some persons who know something are pretty serious about acquiring this stock. I'm tempted to realize some of these gains but am fairly confident we will see higher prices at least by tomorrow's open...after the news is digested by the investing public. I've seen this stock..when it was the previous name and symbol trade from pennies up to a buck. I'd sure hate to miss that sort of gain if that's where we're heading. Best regards.
Has anyone been able to see the 8-K? Someone must know what's going cause at this point I sure don't.
Randy
Eagle...do you HOPE or KNOW Dutton Assc. Will Put out and update? If they do I'm pretty confident they will put out a 12 month target of $2-3.00.
Check out the ADVFN Time and Sales Ratio...
http://ih.advfn.com/p.php?pid=trades&btn=s_ok&symbol=USBB%3Agtec&newdate=0&newsym=1&...
I don't recall the stock even trading as low as .48 in the last months. I remember seeing .56 but not lower. I just checked yahoo...the 52 week low is .55. Oh well.
Best regards.
Randy
Nice Catch on the Recommendation update. I hadn't seen the Redchip research report so was glad to learn more about it.
I'm guessing that within the next month we should see some pretty serious interest in Zanett's upcoming earnings report.
Best regards.
Randy
And the Bad News....There Isn't Any!!!
I scanned the new 8-K and the only thing that caught my eye was a bit of bank indebtedness...I think it was around $13 Million at interest rates of 5-7% ...but for the size of the company I didn't think it sounded too bad.
Also, I was a bit unclear about the retained dividends...of $10 Million. I wasn't clear whether this would be a part of the $17 Million of cash in hand or not....Either way it should be adequate to compensate for debt.
I'm excited.
Audited Financials Show $.06 E.P.S
Here's the link..... http://yahoo.brand.edgar-online.com/fetc...
End result...... Net Income.....earnings per share!!!
.06 per share!!!!!
Let's see .... that equals a PE ratio at current share prices of 5.6.
I can't resist..... Let's run some valuations:
at 10
at 15 $.90
at 20 $1.20
at 25 $1.50
at 30 $1.80
at 40 $2.40
Then just for fun multiply these numbers by the rate of growth that the company has experienced in the past...and that tells you what to expect in the future.
From the way ZANE has traded today, I wouldn't be surprised if we would hear some news in the near future. The way the stock is trading today is at least a little peculiar, don't you think?
One of the Advantages of Trading at Current Levels
As Zanett acquires companies ("Oracle geographies") with some cash and a lot of stock, the recent beaten-down low Zanett stock price has, ironically, afforded the company the rare ability to offer target companies a price in the range of $.65-80/share.
So, for example, stock bought per acquisition at 65c/share has offered target companies the easily attainable ability to at very least, triple their buy-in, at $2/share, as Zanett hits that price shortly.
Needless to say, Zanett has been hard at work trying to take advantaga of the low stock price. Of course, management is aware that the 30 day "delisting" requirement deadline is Sept 25, and Nasdaq will then send them a notice promptly after that, but it is, overall, of little concern, as the company's acquisitions news will easily and quickly bring the stock price over $1 (delisting candidates have up to 180 days to get over $1).
The recent buying push in Zanett from the 65c range to the 80c/share range is in direct response to the aforementioned oppurtunites and related news coming- as savvy investors gear up for Zanett to go up to at least $2 and above.
As Zane continues to acquire Oracle geographies, streamlining margins in their usual proven 1/2 acquisitive to 1/2 organic growth model, and their work on the EAGLE subcontract (beginning shortly) bears fruit, 2008 earnings will finally bear out the company's strong-positive EBITDA goals and allow then the ability to finally retire a lot of debt,
Moreover, Zanett, the best-of-breed, is now squeezing competitors for Oracle consulting work (the more geographies Elison "gives" Zanett, the more of a "lock" Zanett gets on the national picture. It makes sense to have Oracle help a one-stop shop service the "under 1 billion in sales" crowd.
Well TechKim, I just could resist getting back into ZANE. I jumped out and it costed me some...but I did all right by jumping in and out. What are your thoughts on the way the stock is acting? I'll post a Yahoo Discussion Group post in a second...I think the guy is probably right. Randy
I don't know whether their state of incorporation will change but one of the Press Releases said that they will be moving their US Offices to Northern California.
Some Web-site Updates Showing Up At www.genesis-china.net
I was checking out the GTEC website this morning and noticed that there were already some changes showing up.
1. The Name of the Website has already been updated to Genesis Pharmeceutical Enterprises.
http://www.genesis-china.net/
2. The About Us Page has Different Information an October 1, 2007 picture with the following caption: "CEO Cao Wubo leads his experienced army of professionals at the Shandong headquarters. This photo was taken on October 1, 2007, the day the merger was completed."
http://www.genesis-china.net/aboutus.html
3. The Investor Management Page shows new Directors and officers
http://www.genesis-china.net/management.html
There was not much new information from what we've already learned in the press releases...but the following paragraph caught my attention:
JPC has 440 full time sales representatives and 620 part time representatives located in all major commerce areas across China. The company has numerous GMP (Chinese State Drug Administration or the SDA) approved manufacturing facilities and production lines and is approved to produce tablets, capsules and granules. In 2007, LJPC produced 300 million tablets, 50 million bags of granule and 50 million capsules. The Company's top four products include Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Ciprofloxacin Hydrochloride tablets, and Paracetamol tablets.
The merger with GTEC is already completed as of October 1, 2007. Check out the letter from previous management at http://www.genesis-china.net
Outstanding shares on the front page of the referenced 10Q says: "There were 81,111,234 shares of the Registrant’s $.001 par value common stock outstanding as of August 14, 2007."
However, I thought I remembered reading somewhere that the outstanding shares stayed the same. As I'm thinking about, I think the explanation is that the share increase is the allocation of shares for the options set aside for management options. I don't have time to varify.
Promised Events and PRs from Old and New GTEC
From genesis-china.net Shareholder Letter
"The future of Genesis Pharmaceutical Enterprises, Inc. (OTCBB: GTEC) shall be determined by Mr. Wubo Cao, his experienced staff and Board of Directors. In the near future, Mr. Cao will reveal the plans for the Company's future." [bold mine]
"A new website is under construction and should debut soon. "
"The Genesis Equity Partners, LLC, stock portfolio, the assets earned through GTEC's private-to-public business model, shall exist as a subsidiary of the merged Company, under the direction of an appointee of the previous GTEC Board. This portfolio will be methodically liquidated to cover all remaining expenses incurred by GTEC and GEP, with any dividends to be paid out to only U.S. shareholders in GTEC. More details about this subsidiary will be forthcoming."
I have a feeling that after these events are accomplished many of our questions will be answered and we will be looking at a much appreciated share price. :)
Genesis Pharmeceutical's Auditing Company Moore Stevens Has anyone else checked out the company that has already completed the June 30, 2007 pre-merger audit? I had thought to do it earlier, but haven't gotten around to it until this evening. These guys are huge...check it out for yourself.
http://www.mswft.com/company_ahi.htm
Here are some exerpts from their websites:
A History of Unparalleled Service
Since our beginnings in 1918, Moore Stephens Wurth Frazer and Torbet, LLP has continued to gain an unparalleled reputation in the accounting and consulting industry. As one of the oldest and most respected names in our business, we have consistently been noted for our extensive range of high-quality services that include and exceed those of traditional accounting firms. At Moore Stephens Wurth Frazer and Torbet, LLP the breadth and depth of our expertise extends beyond accounting and tax compliance functions to value-added services such as management advisory services, financial planning, valuation services and system implementation. Our goal is to become your strategic partner while providing you with value-added insight and advice on the many complex financial issues that abound in today's marketplace
Size
MSNA, Inc., is a member of Moore Stephens International Limited (MSIL), a multinational consulting and accounting network with headquarters in London, England. MSIL has over 170 independently owned and operated firms and over 380 offices in more than 80 countries.
Global Presence
From Chicago to Moscow to Sydney to Beijing to London, Moore Stephens Wurth Frazer and Torbet, LLP can readily avail ourselves of our international talent pool of nearly 12, 000 professionals. Sound business advice that bridges the gaps of our world cultures, traditions, and languages is easily obtained with our broad-ranging network of firms.
Areas of Specialization
Our commitment to serving companies doing business in Asian countries, especially in China is supported by Moore Stephens International Limited and Moore Stephens member firms in all the Pacific Rim Countries. This group coordinates our client service activities between the USA and all the Asian countries and helps clients address the complex issues frequently encountered while doing business in this rapidly changing marketplace. Our extensive presence ensures our practice has a wealth of local expertise to provide cutting-edge solutions to our local and international clients doing business in Asia.
The success of any organization in all the Asian countries depends on its ability to accommodate the dynamic aspects of the language, cultural and business practices it faces every day as well as the business risks created by these dynamics. Organizations that recognize and skillfully address the impact of these dynamics on their business model and objectives vastly improve their opportunities for success. Others who have addressed these dynamics and risks limit their opportunities and face a more severe challenge. We help companies to close the gaps of the language, cultural and business practices within those countries.
Hello Dark Stat...I think your question has a fairly easy to answer. The data on which these links PE are based is the last financial data filed by the company...in its last 10Q. If you take the market cap of any of these links you provided (if it is listed)and divide it by the share price .34, you will see that it equals the 88 million shares that were outstanding before the merger/acquisition.
So, the projected PE ratios of myself and others are based on the pro forma numbers of the acquired company. The accreditative numbers will not show up in such statistics until the new financial data is filed with the SEC(probably not until the next 10Q is filed).
Market Predictions Vs. Legitimate Valuation
I think we should be careful about making predictions about what the stock is going to do by what date or time. When stocks are hyped like this, I think it opens the door to unreasonable expectations and discontented investors when those expectations are not met.
I have been one of the biggest advocates on this board both before the reverse merger and after. If you look back over the posts to last Monday, you will see that I also made some pretty optimistic projections. However, I think most of these were based on values and worth, not what the market would or would not do by a certain time.
I happen to believe GTEC will eventually reach the share prices suggested by many on this board (and probably surpass them in time). However, I doubt we will reach them in just a few days. I think day traders can make some easy money with this stock, but its going to be the value investors that do the best.
Patience and confidence will be richly rewarded.
In answer to your questions:
"the new GTEC has enough assets to be listed on NASDAQ or AMEX. Don't you agree?"
I don't actually know the qualifications for listing on the various exchanges or but I have read posts on the boards that suggest that this is the case.
"And isn't most of the 300M shares that GTEC will have to issue be restricted?"
Absolutely. The Merger document in the 8-K make this explicitely clear.
When Comparing GTEC to AOB remember the valuation is affected by the number of shares outstanding. For instance if AOB would have 400,000,000 million shares outstanding it would warrant only 1/5 the price as it currently has approximately 1/5 the number of shares outstanding (74.4 Million). Doing the equal comparison $12.50/5 equals $2.50 per share.
NOTE, the market cap comparison is of great interest. AOB Market Capitalization $926,000,000. If we are a comparable company which sounds probably that would translate to $2.31 per share with our current shares outstanding.
Run that through your calculators. How nice that would be. Do you have the patience to wait for it? I ask myself the same question.
I grabbed the time and sales link from someone else a few days ago. It's delayed but a great service. Just bookmark the link and enter in company ticker symbol of your choice.
http://ih.advfn.com/p.php?pid=trades&btn=s_ok&symbol=USBB%3Agtec&newdate=0&newsym=1&...
Running the Numbers if Shares are Reverse Split 1:7
Same amount of pie...just bigger pieces. Reverse Splitting the stock for no reason doesn't make much sense. However, reverse splitting to make the stock NASDAQ and marginable---HUGE. For instance...if you would pare the outstanding shares sevenfold...400,000,000/7 that would reduce our oustanding shares to 57.1 million and the float to just over 10 million. The Revenue, Earnings and Asset value would all stay the same, just divided by a smaller number:
Earnings: $22,000,000/57,100,000 equals $.38 per share.
Book Value: $55,000,000/57,100,000 Equals $.96 per share
Look at the share price at the different PE ratios:
10 would mean a share price of $3.80
20 would mean a share price of $7.60
30 would mean a share price of $11.40
No matter which outcome they choose, it will be a win win. Another of the advantages of a reverse split is that it allows bigger brokerage houses to recommend the stock to their clients. Some firms won't let brokers recommend shares under $5.00.
By all this don't think I'm naive or wanting a reverse Split...I'm just pointing out that its not all that bad and can be potentially good, especially when you have a profitable growing company.
Awesome Eagle....the letter on the http://www.Genesis-china.net website finishes with a picture of the same guy. Amazing.
So far today there has been more buying than selling!!
Earlier today this was not the case. I think this bodes well for stock price and close.
http://ih.advfn.com/p.php?pid=trades&btn=s_ok&s_symbol_select=NASDAQ%3AZANE&symbol=gtec&....
Doc, Early on I stated that it sounded to like they were going to be distributing the shares of their public-to-private companies to the prior GTEC shareholders.
However, in the shareholder letter they spelled this out a bit more. They will use those assets to meeting the expenses and such from the old GTEC. The shares will be liquidated and the proceeds, if any, will be distributed to the non-Laiyang Jiangbo Pharmaceuticals (75%) shareholders.
I am not clear how much this will be. Certainly .08 to .25 would not be out of line. LTUS has been trading at $1.30 per share (and higher) while SPEH (Jin Ma--Gold Horse) has not been trading much....but is certainly worth a $1.00-2.00 per share. Whether they will be able to get that much remains to be seen. My .08-.25 estimate assumes they won't.
DREAM WITH ME....let's say they got $1.00 per share of both SPEH and LTUS shares. That would be roughly $24,000,000 bucks. Divide that by 85,000,000 and each share would receive a distribution of 28 cents per share. :)
THIS WOULD BE GREAT BUT I'D RATHER JUST GET THE SHARES!!!!!
According to the last 10Q GTEC owns 16,750,000 shares of SPEH,(which is JinMa) and I don't know for sure but let's guess that there are around 8 million shares of LTUS still owned by the company. If these were distributed directly each GTEC shareholder (of the 85 Million) would get like .1 shares of LTUS and .2 shares of SPEH. I think it'd be amazing to get a distribution like that. At that rate each 10000 shares of GTEC would get 1000 shares of LTUS and 2000 shares of SPEH.
The Bloomburg quote is in Euros....to get to USD one multiplies by 1.42 (at least that's someone showed yesterday)....so on the Frankfurt exchange: Bid .197EU Ask .204EU or .27974 to .28968. That's pretty comparable.
What is GTEC Post Merger Valuation?
By Profits: (These are trailing numbers....not projected)
With audited net profit of .055 per share It should be valued between 330 and 660 Million.
Basis: PE of 15 or $.825 x 400,000,000 Total: $330,000,000
PE of 20 or $1.10 x 400,000,000 Total: $440,000,000
PE of 30 or $1.65 x 400,000,000 Total: $660,000,000
By Revenue: (Peer companies vary but 5-7 is common)
$76,000,000 x 5 ='s $380,000,000 or $.95 per share
$76,000,000 x 6 ='s $456,000,000 or $1.14 per share
$76,000,000 x 7 ='s $532,000,000 or $1.33 per share
Actually the PE at this price 4.7!!!!
Ownership of Post Merged Company From SEC 8-K
PROJECTED OWNERSHIP PERCENTAGES (First three columns found in 8K. I projected the last collumn Post Issued Shares.) What it means? A lot of people entrusted our CEO Cao Wubo and he has delivered as promised. I think we can trust him to deliver too!
Schedule A
Name Amount of Karmoy Amount of GTEC Amount of GTEC Post Issued
Shares Common Stock Preferred Stock Shares (%)
Wang Shuo 267 39 159,887 7,994,350 (2%)
Ai Yunian 400 34 239,831 11,991,550 (3%)
Zhao Qun 267 39 159,887 7,994,350 (2%)
Chang Zhaozhen 133 45 79,943 3,997,150 (1%)
Cawston Enterprises 400 34 239,831 11,991,550 (3%)
Greenview Capital* 267 39 159,887 7,994,350 (2%)
Cao Wubo** 4,215
Xun Guihong** 3,224
Zhang Yihua** 827
* GTEC Shares to be held in escrow pending a $30 million financing of GTEC equity securities assisted by Greenview Capital.
The stock certificate for Greenview Capital shall be sent to Gary Wolfson at 7900 Glades Road, Suite 420, Boca Raton, Florida 33434.
** GTEC Shares to be issued to Cao Wubo, Xun Guihong and Zhang Yihua shall be assigned to other third parties as set forth on the next page.
ASSIGNEES OF THREE (3) LJPC SHAREHOLDERS
Name Amount of GTEC Amount of GTEC Post Issued
Common Stock Preferred Stock Shares (%)
Verda International Limited 11 3,885,273 144,263,650 (36%)
Wang Renhui 40 447,685 22,384,250 (5%)
Wang Xin 39 159,887 7,994,350 (2%)
Han Cuifen 39 159,887 7,994,350 (2%)
Cui Baohong 34 95,932 4,796,600 (1.1%)
Liu Defu 19 7,994 399,715 (.1%)
Wang Shuzhong 19 7,994 399,715 (.1%)
Zhang Qingjun 39 15,988 799,400 (.2%)
Xing Jun 19 7,994 399,715 (.1%)
Ge Jian 19 7,994 399,715 (.1%)
Zhang Guijun 19 7,994 399,715 (.1%)
Feng Shusen 45 79,943 3,997,150 (1%)
Ju Hongying 25 71,949 3,597,450 (.9%)
I have no doutb this is the same company. It mentions our new CEO and Chairman of the Board. Great work. Sounds great!! Thanks for the DD.
Why GTEC Has Gone Upand Will Go Further
To affect the acquisition GTEC has to issue 300,000,000 shares. However it's authorized is only 200 Million. So, GTEC issued 5.99 Million shares of Preferred B which will immediately convert 1 for 50 GTEC shares when a shareholder meeting is held and authorizes 600 Million or so shares. Their prefered shares will equal appr. 300,000,000 shares. This means that theoretically there are 400,000,000 shares outstanding...some say 385 Million...who knows.
The INDISPUTABLE FACTS ARE...We have a company...
With $17 million cash on hand...that .0425 per share...
With $22 million net income...that's EPS of .055
Which should warrant...
At a PE ratio of 15.....82.5 cents
At a PE ratio of 20.....$1.10
At a PE ratio of 30.....$1.65
This deal is huge and will appreciate.
Why Laiyang Jiangbo Pharmaceuticals Become a Public Company?
Now let’s think this through. Does anyone think that the new CEO and Chairman of the Board, Mr. Wubo Cao, went through the private to public process to have his company produce a market cap of 120 million? I don’t think so. Heck even if revenues and net income don’t change, it would earn this much income in only six years. At half the rate previous growth the new GTEC would earn this much in less than 4 years.
The truth is this company deserves a market cap of 500 million or more. That would require a stock price of $1.25+. Just be patient.
SELLING THIS STOCK AT LOW PRICES COULD BECOME ONE OF YOUR BIGGEST MISTAKES!!